Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the drug-drug interaction between AL-3778 and entecavir or tenofovir disoproxil fumarate (Part 3).

Study Overview

• Status: Terminated
• Conditions: Hepatitis B; Chronic Hepatitis B; Viral Hepatitis B
• Intervention / Treatment: Drug: AL-3778; Drug: Entecavir; Drug: Tenofovir disoproxil fumarate

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 1

Contacts and Locations

Study Locations

• New Zealand
  • Auckland, New Zealand, 1010
    • Auckland Clinical Studies
  • Christchurch, New Zealand, 8011
    • Christchurch Clinical Studies Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 56 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Inclusion Criteria for All Subjects:

1. Subject has provided written consent.
2. In the investigator's opinion, the subject is able to understand and comply with protocol requirements, instructions, and study restrictions and is likely to complete the study as planned.
3. Subject is in good health as deemed by the investigator, based on the totality of findings following a medical evaluation, including medical history, physical examination, laboratory tests and ECG.
4. Male or female, 18-60 years of age.
5. Body mass index 18-30 kg/m2, inclusive. The minimum weight is 50 kg.
6. A female subject is eligible to participate in this study if she is of non-childbearing potential (defined as females with a documented tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as 12 months of spontaneous amenorrhea and follicle stimulating hormone level within the laboratory's reference range for postmenopausal females). A post-menopausal female receiving hormone replacement therapy who is willing to discontinue hormone therapy 28 days before study drug dosing and agrees to remain off hormone replacement therapy for the duration of the study may be eligible for study participation.
7. If male, subject is surgically sterile or practicing required forms of birth control until 6 months after the last dose of the study drug(s). Males must agree to refrain from sperm donation from check-in through 6 months after the last dose of the study drug(s).
8. Subject has been a nonsmoker and has not used nicotine or nicotine-containing products for at least 6 months.
9. Subjects who participated in Part 1 and/or Part 2 may participate in subsequent Part(s) upon satisfactory completion of a posttreatment visit, 7 days (+2 days) following the subject's last dose, and provided they continue to meet all of the inclusion criteria and none of the exclusion criteria.

Main exclusion criteria:

1. Subject is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last 5 to 10 years.
2. Subject has a history of any illness that, in the opinion of the investigator, would confound the objectives or results of the study or poses an additional risk to the subject by their participation in the study.
3. Subject has an estimated creatinine clearance of ≤80 mL/min based on the Cockcroft-Gault equation; An actual creatinine clearance, as determined by a 24-hour urine collection, may be used in place of, or in conjunction with, the Cockcroft-Gault equation; subjects who have an actual or estimated creatinine clearance within 10% of 80 mL/min may be enrolled in the study at the discretion of the investigator.
4. Pregnant or nursing (lactating) females, confirmed by a positive human chorionic gonadotropin laboratory test or females contemplating pregnancy. Men whose female partners are pregnant or contemplating pregnancy from the date of screening until 6 months after their last dose of study drugs.
5. Clinically significant cardiovascular, respiratory, skeletal, renal, gastrointestinal, hematologic, hepatic, immunological, neurologic, endocrine, genitourinary abnormalities or disease or any other medical illness as determined by the investigator or Sponsor's Medical Monitor.
6. Subject has a history of malignancy except completely excised basal cell carcinoma or squamous cell carcinoma of the skin.
7. Subject lacks or has poor peripheral venous access.
8. Positive screening result for hepatitis B, hepatitis C and/or HIV serology.
9. Any condition that, in the opinion of the investigator, would compromise the study's objectives or the well-being of the subject or prevent the subject from meeting the study requirements.
10. Clinically significant abnormal ECG findings. Particularly, a history or family history of prolonged QT syndrome (eg, torsade de pointes) or sudden cardiac death.
11. ECG with PR >200 ms, QRS >120 ms, QTcF >450 ms, as assessed by triplicate 12-lead ECG at the screening visit.
12. Subject has had major surgery, or clinically significant blood loss or elective blood donation of significant volume (ie, >500 mL) within 60 days of first dose of study drug; >1 unit of plasma within 7 days of first dose of study drug.
13. Abnormal heart rate, respiratory rate, temperature or blood pressure values outside of the normal range (evaluated in a semi-recumbent or recumbent position after 5 minutes of rest). One repeat measurement after an additional 5 minutes of rest is permitted.
14. Evidence of active infection.
15. Unwilling to abstain from alcohol for at least 48 hours prior to the start of dosing through the study completion visit.
16. History of regular alcohol intake >7 units per week of alcohol for females and >14 units per week for males (one unit is defined as 10 g alcohol) within 3 months of the screening visit.
17. The subject has a positive screening or Day -1 drugs of abuse screen.
18. The use of concomitant medications, including prescription, over the counter medications, and herbal medications (such as St. John's Wort [Hypericum perforatum]) within 30 days prior to the first dose of study medication is excluded, unless approved by the Sponsor's Medical Monitor. Occasional use of ibuprofen/paracetamol/ acetaminophen is permitted.
19. Subject has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the planned study drug.
20. Subject has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.
21. Hypersensitivity to the active substances or to any of the excipients of AL-3778, entecavir or tenofovir disoproxil fumarate.
22. Subject has known allergy to heparin or history of heparin-induced thrombocytopenia.
23. Abnormal biochemistry or hematology laboratory results obtained at screening determined to be clinically significant by the Investigator. Screening ALT, AST, GGT, albumin, and total bilirubin must be within normal ranges. Creatine kinase >1.5 x ULN is exlusionary
24. Unwillingness or inability to comply with the study protocol for any other reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatments A, B, C; Part 1: Cross-Over; Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.; Treatment B: AL-3778 2 x 300-mg tablets (fasted) once; Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once.	Drug: AL-3778; AL-3778 tablets or capsules; Other Names: NVR 3-778, JNJ-63595948, ALS-003778
Experimental: Treatments D, E, F; Part 2 (optional): Cross-Over; Treatment D: AL-3778 2×300-mg tablets (fasted) once.; Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:; 1000mg: 2 x 500-mg OR; 800mg: 1 x 300-mg + 1 x 500-mg OR; 700mg: 1 x 200-mg + 1 x 500-mg; Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:; 1000mg: 2 x 500-mg OR; 800mg: 1 x 300-mg + 1 x 500-mg OR; 700mg: 1 x 200-mg + 1 x 500-mg	Drug: AL-3778; AL-3778 tablets or capsules; Other Names: NVR 3-778, JNJ-63595948, ALS-003778
Experimental: Treatment G; Part 3: AL-3778 twice daily administered under fasted conditions for 14 days. Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages: 600mg: 2 x 300-mg OR; 1000mg: 2 x 500-mg OR; 800mg: 1 x 300-mg + 1 x 500-mg OR; 700mg: 1 x 200-mg + 1 x 500-mg	Drug: AL-3778; AL-3778 tablets or capsules; Other Names: NVR 3-778, JNJ-63595948, ALS-003778
Active Comparator: Treatment H; Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days	Drug: Entecavir; Entecavir once daily for 14 days
Experimental: Treatment I; Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days. AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages: 600mg: 2 x 300-mg OR; 1000mg: 2 x 500-mg OR; 800mg: 1 x 300-mg + 1 x 500-mg OR; 700mg: 1 x 200-mg + 1 x 500-mg	Drug: AL-3778; AL-3778 tablets or capsules; Other Names: NVR 3-778, JNJ-63595948, ALS-003778; Drug: Entecavir; Entecavir once daily for 14 days
Active Comparator: Treatment J; Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days	Drug: Tenofovir disoproxil fumarate; Tenofovir disoproxil fumarate once daily for 14 days; Other Names: Viread
Experimental: Treatment K; Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days. AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages: 600mg: 2 x 300-mg OR; 1000mg: 2 x 500-mg OR; 800mg: 1 x 300-mg + 1 x 500-mg OR; 700mg: 1 x 200-mg + 1 x 500-mg	Drug: AL-3778; AL-3778 tablets or capsules; Other Names: NVR 3-778, JNJ-63595948, ALS-003778; Drug: Tenofovir disoproxil fumarate; Tenofovir disoproxil fumarate once daily for 14 days; Other Names: Viread

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
AL-3778, entecavir, tenofovir: Maximum observed plasma concentration (Cmax)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Area under the plasma concentration-time curve from time 0 to last measurable concentration (AUClast)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUC∞)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Maximum observed plasma concentration on Day 1 (Cmax. Day 1)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1
AL-3778, entecavir, tenofovir: Minimum observed plasma concentration on Day 1 (Cmin, Day 1)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1
AL-3778, entecavir, tenofovir: Area under the plasma concentration-time curve from time 0 to dosing interval on Day 1 (AUC0-Τ, Day 1)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1
AL-3778, entecavir, tenofovir: Minimum observed plasma concentration (C_min)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22

Secondary Outcome Measures

Outcome Measure	Time Frame
AL-3778, entecavir, tenofovir: Predose plasma concentrations (C_0-h)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Last observed plasma concentration (C_last)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Time of the maximum observed plasma concentration (T_max)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Time to last measurable plasma concentration (T_last)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Apparent oral clearance (CL/F)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Apparent volume of distribution (Vz/F)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Apparent terminal half-life (t½)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14 and once per day on Day 8, 10, 12, and 22
AL-3778, entecavir, tenofovir: Maximum observed plasma concentration on Day 14 (Cmax. Day 14)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 14
AL-3778, entecavir, tenofovir: Minimum observed plasma concentration on Day 14 (Cmin, Day 14)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 14
AL-3778, entecavir, tenofovir: Area under the plasma concentration-time curve from time 0 to dosing interval, tau, on Day 14 (AUC0-Τ, Day 14)	At 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hours after dosing on Day 1 and 14
Incidence, nature, and severity of adverse events	Screening to Day 22
Changes in Vital Signs during and after study drug administration	Day 1 to Day 22
changes in physical examinations during and after study drug administration	Day 1 to Day 22
changes in clinical laboratory results during and after study drug administration	Day 1 to Day 22
changes in electrocardiogram results during and after study drug administration	Day 1 to Day 22

Collaborators and Investigators

• Sponsor: Alios Biopharma Inc.
• Investigators: Study Director: William D Kennedy, MD, Alios Biopharma Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 31, 2017
• Primary Completion (Actual): June 28, 2017
• Study Completion (Actual): June 28, 2017

Study Registration Dates

• First Submitted: January 24, 2017
• First Submitted That Met QC Criteria: January 24, 2017
• First Posted (Estimate): January 26, 2017

Study Record Updates

• Last Update Posted (Actual): October 16, 2017
• Last Update Submitted That Met QC Criteria: October 13, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir; Entecavir
• Other Study ID Numbers: AL-3778-1002; U1111-1187-4391 (Registry Identifier: WHO)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Data will be provided per regulatory requirements.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No